Health Economics›Breast cancer›Unselected all lines of therapy

Unselected all lines of therapy

Breast cancer · 7 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 6 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Eribulin monotherapy Variant #01	—	R 22 427	21d	~4.1 mo	~13.1 mo	~2	~R 44 854 PFS proxy · indirect	22
nab-Paclitaxel monotherapy Variant #01	—	R 16 043	28d	~5.6 mo	~16.8 mo	~2	~R 32 087 PFS proxy · indirect	12
Ixabepilone monotherapy Variant #01	—	R 15 504	21d	—	~7.5 mo	~2	~R 31 009 PFS proxy · indirect	1
Docetaxel monotherapy Variant #02	—	R 2 921	28d	~8.0 mo	~11.5 mo	~7	~R 20 450 PFS proxy · indirect	11
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~4.6 mo	~11.0 mo	~7	~R 11 705 PFS proxy · indirect	16
Paclitaxel monotherapy Variant #02	—	R 734	28d	~6.4 mo	~16.8 mo	~6	~R 4 406 PFS proxy · indirect	28
Vinorelbine monotherapy Variant #01	—	R 458	21d	~4.0 mo	~10.1 mo	~7	~R 3 203 PFS proxy · indirect	18

7 of 7 regimens shown